Medivir carries out a directed share issue of approx. SEK 20 million
INSIDER INFORMATION: Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) (“Medivir” or the “Company”), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the board of directors of MedivirAB (publ), as authorised by the general meeting on 4 May 2023, has resolved on a directed issue of 7,547,170 new ordinary shares through which the Company receives approx. SEK 20 million before issue costs (the “Directed Issue”). The right to subscribe for shares in the Directed Issue shall, with deviation from the